Biosimilar Solutions Reports the Initiation of Registrational Clinical Trials for Biosimilar BSC0826 to Treat Cancer
Shots:
- The company initiates its registrational clinical trial to evaluate the biosimilar version of Neulasta vs Neupogen (filgrastim) for cancer. The US FDA has reviewed & approved the study design of the trial
- The company has established the manufacturing & operations agreement with OcyonBio & plans to complete a technology transfer in 2022 with an expected product launch in 2023
- The company will build a facility in Aguadilla in OcyonBio's Campus in Puerto Rico for BSC0826 production. PEG-GCSF helps to increase the no. of neutrophils & reduces inf. in cancer patients along with an increased survival rate in patients exposed to harmful radiation that causes bone marrow damage
Ref: Globe Newswire | Image: OcyonBio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
